FX-322 in Adults With Severe Sensorineural Hearing Loss
Status:
Active, not recruiting
Trial end date:
2021-09-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1b, prospective, randomized, double-blind, placebo-controlled, single-dose,
multicenter, safety study of FX-322, administered by intratympanic injection, in adults with
severe sensorineural hearing loss.